// Biotech and Pharma Therapeutics
Advanced Primary Care 2026: Top 6 Investments for Health Systems According to Harvard Medical School
December 24, 2025 / advanced primary care / behavioral health integration / chronic disease management / primary care ROI / healthcare transformation
Harvard Medical School’s guide identifies six high-impact, ROI-driven primary care investments—including behavioral health, pharmacy integration, and e-consults—critical for transforming reactive clinics into proactive, value-based care hubs amid growing national primary care shortages.
The Pharmacy Closures Crisis: How Independent Pharmacies Are Fixing Pharmacy Deserts
December 24, 2025 / pharmacy deserts / medication adherence / independent pharmacies / healthcare access / rural health services
Independent pharmacies are stepping in to address growing pharmacy deserts caused by national chain closures, offering personalized care, medication adherence support, and tech-enabled outreach to improve access, especially in underserved and rural communities.
China’s biopharma ascent signals shift in global drug development leadership
December 24, 2025 / China biopharma growth / global drug development / biologics innovation / regulatory reform China / pharma industry trends
China now represents 20% of global drug development, surpassing Europe, driven by regulatory reform and innovation in biologics—marking a major shift in global biopharma research, development, and collaboration strategies.
3 drug policy questions to watch in 2026
December 24, 2025 / drug policy 2026 / harm reduction debate / addiction treatment policy / supervised consumption laws / mental health funding
In 2026, U.S. drug policy faces uncertainty as federal actions target harm reduction efforts, raising concerns among addiction specialists amid agency cutbacks and political shifts impacting mental health and substance use strategies.
Mega-deals mask a cautious year for medtech M&A
December 23, 2025 / medtech M&A 2025 / digital health investments / diagnostics acquisitions / connected care platforms / regulatory due diligence
Medtech M&A value soared to $92.8B in 2025 due to three mega-deals, despite overall deal volume remaining low. Investors now prioritize digital scalability, clinical impact, and regulatory readiness in imaging, diagnostics, and connected care technologies.
// 4th Industrial Revolution
AI seen as pharma’s most disruptive technology, GlobalData finds
December 24, 2025 / AI drug discovery / pharma digital transformation / R&D cost reduction / predictive analytics healthcare / biopharma technology trends
AI is the most disruptive technology in pharma, accelerating drug discovery, cutting R&D costs, and improving patient outcome predictions by analyzing complex datasets at scale, according to GlobalData’s 2026 biopharma industry report.
Automated system improves deep learning accuracy in chest radiography analysis
December 24, 2025 / radiology AI tools / chest X-ray labeling / deep learning radiography / medical imaging accuracy / automated image analysis
Osaka researchers developed automated models that detect and correct labeling errors in chest X-rays, significantly improving deep-learning model accuracy in clinical radiography analysis with over 98% precision for body part, projection, and rotation verification.
Stop the $150B Drain: Using AI Agents to Fix Missed Appointments
December 23, 2025 / AI appointment reminders / patient no-show reduction / healthcare automation tools / missed appointment prevention / predictive health analytics
AI-powered systems can reduce missed healthcare appointments by predicting high-risk no-shows with up to 90% accuracy, enabling targeted outreach and improved patient engagement—saving U.S. health systems billions in lost revenue and enhancing care access.
Executive predictions for healthcare AI in 2026, Part 2
December 22, 2025 / healthcare AI trends / personalized health insights / AI in clinical workflows / patient-centered AI tools / future of medical AI
Healthcare AI in 2026 is expected to shift from generating information to curating personalized insights, streamlining clinical and administrative tasks while improving patient focus and reducing information overload for more effective, individualized care.
Artificial intelligence improves risk stratification in oropharyngeal cancer
December 23, 2025 / oropharyngeal cancer / AI cancer tools / extranodal extension prediction / cancer risk stratification / personalized oncology treatment
Researchers developed an AI tool that uses CT imaging to predict extranodal extension in oropharyngeal cancer, improving risk stratification and guiding personalized treatment decisions, including intensification or de-intensification of therapy.
// Business & Markets
NewCos: the new exit strategy?
December 24, 2025 / NewCo biotech trend / bispecific antibody cancer / ABL Bio spinout / oncology drug development / biotech venture funding
Neok Biotech, a NewCo spun out from ABL Bio, raised $75M to develop bispecific antibody conjugates targeting gastrointestinal and gynecological cancers—highlighting NewCos as a growing exit and investment strategy in biotech innovation.
Shionogi inks hearing loss deal with Salubritas Therapeutics
December 24, 2025 / hearing loss treatment / hair cell regeneration / sensorineural hearing loss / Shionogi Salubritas partnership / hearing restoration drug
Shionogi and Salubritas Therapeutics have partnered to develop therapies targeting sensorineural hearing loss by regenerating sensory hair cells in the inner ear, aiming to address a major unmet need in hearing restoration.
HCAP Partners Invests in Puzzle Healthcare to Scale Post-Acute Care Platform
December 19, 2025 / post-acute care / hospital readmissions / SNF care coordination / value-based healthcare / physiatry integration
HCAP Partners has invested in Puzzle Healthcare to expand its 90-day post-acute care model, which embeds physiatrists and care managers in SNFs to reduce costly hospital readmissions and support value-based care across 230 facilities nationwide.
Tebra scores $250M for EHR+ platform and more digital health funding news
December 23, 2025 / AI healthcare platform / EHR investment news / pediatric obesity care / digital health funding / virtual clinic expansion
Tebra raised $250M to expand its AI-driven EHR and practice management platform for private practices, while Clarity Pediatrics secured $14.5M to launch pediatric obesity care and grow its virtual clinic platform nationwide in 2026.
Valerie Health Snags $30M to Advance AI Front Office for Independent Provider Groups
December 23, 2025 / AI healthcare automation / independent provider tech / clinical workflow AI / digital health funding / front office efficiency
Valerie Health raised $30M to expand its AI-powered front office platform, automating workflows like referrals and scheduling for independent provider groups to reduce administrative burden, improve efficiency, and support practice growth and staff satisfaction.
// Legal & Regulatory
Sanofi’s Vaccine Lineup Gets a Shot in the Arm With $2.2B Dynavax Acquisition
December 24, 2025 / Sanofi acquisition / hepatitis B vaccine / shingles vaccine development / Dynavax deal 2025 / vaccine market expansion
Sanofi acquired Dynavax for $2.2B, adding a differentiated hepatitis B vaccine and a clinical-stage shingles vaccine to its pipeline, strengthening its position in the global vaccine market and competing directly with GSK offerings.
US FDA rejects Sanofi filing for tolebrutinib in progressive MS
December 24, 2025 / Sanofi tolebrutinib rejection / progressive MS treatment / FDA CRL MS / BTK inhibitor MS / multiple sclerosis drug setback
The FDA issued a Complete Response Letter rejecting Sanofi’s application for tolebrutinib in non-relapsing secondary progressive MS, delaying potential approval of the oral BTK inhibitor. Sanofi plans continued engagement to address regulatory concerns.
Nineteen states, D.C. sue HHS over gender-affirming care crackdown
December 24, 2025 / gender affirming care / HHS lawsuit states / RFK Jr healthcare / Medicaid transgender policy / federal health regulation
Nineteen states and D.C. sued HHS, alleging Health Secretary RFK Jr.’s declaration rejecting gender-affirming care bypassed regulatory procedures and unlawfully impacts state Medicaid programs and medical regulation authority.
Japanese approval for Senju’s Avarept
December 24, 2025 / Avarept approval Japan / TRPV1 dry eye / Senju motugivatrep DED / dry eye treatment Japan / ophthalmic drug approval
Japan approved Senju’s Avarept (motugivatrep), the first TRPV1 antagonist eye drop for dry eye disease, after Phase III trials showed significant symptom improvement. The novel treatment addresses rising DED prevalence due to aging and screen use.
Formycon secures FDA approval for ranibizumab biosimilar Nufymco
December 24, 2025 / Nufymco FDA approval / ranibizumab biosimilar USA / Formycon Lucentis alternative / diabetic eye disease treatment / wet AMD biosimilar
Formycon has received FDA approval for Nufymco, a ranibizumab biosimilar interchangeable with Lucentis, for treating wet AMD and diabetic eye diseases. The approval enhances Formycon’s U.S. ophthalmology presence and supports broader market access strategies.
// Research & Development
Scientists reverse Alzheimer’s in mice and restore memory
December 24, 2025 / Alzheimer’s reversal research / brain energy Alzheimer’s / memory restoration treatment / Alzheimer’s biomarkers mice / cognitive recovery therapy
Researchers have reversed Alzheimer’s in mice by restoring brain energy balance, leading to repaired pathology, normalized biomarkers, and recovered memory—even in advanced stages—offering new therapeutic hope for treating the disease.
First oral anemia treatment across thalassaemia types approved in USA
December 24, 2025 / thalassaemia oral treatment / mitapivat anemia approval / Aqvesme FDA thalassaemia / non-transfusion thalassemia therapy / rare blood disorder drug
The FDA has approved Aqvesme (mitapivat) as the first oral treatment for anemia in both alpha- and beta-thalassaemia, offering a disease-modifying option for transfusion-dependent and non-dependent adult patients.
This tiny peptide could help stop brain damage after injury
December 24, 2025 / CAQK brain injury / neuroprotective peptide therapy / traumatic brain inflammation / IV brain injury treatment / peptide clinical trial
The CAQK peptide targets injured brain tissue post-trauma, reducing inflammation and cell death in animal models. Delivered via IV, it improved recovery in mice and pigs, supporting its potential as a neuroprotective therapy in humans.
These nanoparticles kill cancer cells while sparing healthy ones
December 24, 2025 / cancer killing nanoparticles / targeted cancer therapy / nanoparticle cancer treatment / selective cancer cell death / metal-based oncology research
Scientists developed metal-based nanoparticles that selectively kill cancer cells by amplifying internal stress, triggering self-destruction while sparing healthy cells. This early-stage technology shows promise for more targeted and less toxic cancer therapies.
Your roommate’s genes may be shaping your gut bacteria
December 23, 2025 / gut microbiome genetics / microbiome social influence / genetic microbiome sharing / roommate gut bacteria / microbiome gene interaction
Researchers found that both an individual’s genes and the genes of their social partners influence gut microbiome composition, revealing that genetic effects can spread indirectly through microbial sharing in shared environments.
// Politics
CMS Launches WISeR Model: New Medicare Prior Authorization Rules Start Jan. 1
December 23, 2025 / Medicare prior authorization / CMS WISeR model / healthcare AI regulation / utilization management ML / Medicare fraud prevention
CMS’s WISeR model introduces new Medicare prior authorization rules using machine learning to reduce waste and fraud, but concerns persist about AI-driven decisions delaying care, increasing provider burden, and compromising patient access without strong oversight and clinician involvement.
Trump administration’s plan to shrink vaccine schedule sends health sector scrambling
December 23, 2025 / childhood vaccine schedule / Trump vaccine plan / U.S. immunization changes / pediatric vaccine policy / public health impact
The Trump administration may reduce the U.S. childhood vaccine schedule, possibly eliminating vaccines for chickenpox, hepatitis A, and others. Health leaders warn this could significantly impact disease prevention, sparking legal, political, and public health concerns.
U.K.’s state-owned investment bank shows up in the U.S., eager to spend on biotech
December 19, 2025 / UK biotech investment / British Business Bank / life sciences funding / biotech venture capital / UK pharma growth
The U.K.’s state-owned British Business Bank is courting U.S. biotech investors to strengthen the U.K. life sciences sector, armed with over $34 billion in capital and a new fund supported by local pension plans.
FDA voucher program has become vehicle for political interference in drug review decisions, staffers say
December 19, 2025 / FDA review interference / drug approval politics / priority review vouchers / White House drug influence / FDA internal concerns
FDA staff report political interference in the agency’s new “Commissioner’s National Priority Review” voucher program, raising concerns that White House influence is bypassing scientific review standards and compromising drug safety and approval processes.
White House unveils largest batch of drug pricing agreements yet
December 19, 2025 / drug pricing agreements / pharmaceutical cost reduction / Trump health policy / insurance affordability crisis / international drug price comparison
The Trump administration announced its largest batch of drug pricing agreements yet, with nine pharmaceutical companies committing to price reductions aligned with international benchmarks, as the White House also signals a push to lower health insurance costs next.